The UPC Playbook: European Patent Strategy, IP Valuation, and What Pharma Gets Wrong About Central Revocation
The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that […]
Generic Drug Market Gaps: How to Find, Evaluate, and Own Low-Competition ANDA Opportunities
The Economics Behind Low-Competition Generic Markets Why Price Decay Makes Niche Sourcing Mandatory Generic drug markets operate on a compression
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech
1. Who This Guide Is For This guide is written for IP counsel, portfolio managers, R&D leads, and institutional investors
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech Read Post »
The 2026 Pharmaceutical Innovation Frontier: A Strategic Analysis of AI Dominance, China’s Ascent, and the Patent Cliff Landscape
Executive Summary The global biopharmaceutical sector has entered a decisive inflection point in early 2026, characterized by the convergence of
The Power of Patience: The Pharma Playbook for Extending Market Exclusivity
What Patent Timing Actually Decides A pharmaceutical patent filed on Day 1 of discovery and a patent filed after Phase
The Power of Patience: The Pharma Playbook for Extending Market Exclusivity Read Post »
Lipitor’s Patent Cliff Playbook: How Pfizer Kept 40% Market Share After Generic Entry — and What It Means for Your LOE Strategy
Atorvastatin lost its primary patent on November 30, 2011. What followed was the most studied loss-of-exclusivity response in pharmaceutical history.
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams
1. Why Patent Portfolio Management Determines Market Survival Pharmaceutical patent portfolio management is not a legal overhead function. It is
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams Read Post »
China’s Pharmaceutical Patent Litigation System: The Complete IP Enforcement Playbook for Pharma and Biotech
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making
Drug Patent Exclusivity: What the USPTO Study Actually Tells IP Teams, Portfolio Managers, and Generic Challengers
Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the
